Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityNo recent work listed

Zhengdong Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0234-5478; OpenAlex author ID A5000195252. Sources: OpenAlex.

Their work

Papers
25 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2015: 4 papers · 2016: 5 papers · 2017: 4 papers · 2018: 8 papers · 2019: 3 papers · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 25

  1. Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215976↗
  2. Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants. First author DOI 10.1038/s41379-019-0317-6↗
  3. Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1. Co-author DOI 10.1111/cpr.12514↗
  4. High glucose microenvironment accelerates tumor growth via SREBP1-autophagy axis in pancreatic cancer. Co-author DOI 10.1186/s13046-019-1288-7↗
  5. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. Co-author DOI 10.1016/j.lfs.2018.07.046↗
  6. Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1α. First author DOI 10.1016/j.yexcr.2018.07.041↗
  7. Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways. Co-author DOI 10.1155/2018/9482018↗
  8. Activation of Nrf2 by Sulforaphane Inhibits High Glucose-Induced Progression of Pancreatic Cancer via AMPK Dependent Signaling. First author DOI 10.1159/000494547↗
  9. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions. Co-author DOI 10.1186/s13046-018-0740-4↗
  10. Curcumin inhibits superoxide dismutase-induced epithelial-to-mesenchymal transition via the PI3K/Akt/NF-κB pathway in pancreatic cancer cells. First author DOI 10.3892/ijo.2018.4295↗
  11. Itraconazole inhibits invasion and migration of pancreatic cancer cells by suppressing TGF-β/SMAD2/3 signaling. Co-author DOI 10.3892/or.2018.6281↗
  12. Norepinephrine enhances cell viability and invasion, and inhibits apoptosis of pancreatic cancer cells in a Notch‑1‑dependent manner. Co-author DOI 10.3892/or.2018.6696↗
  13. Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1-dependent pathway. Co-author DOI 10.1002/1878-0261.12116↗
  14. Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2016.10.019↗
  15. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Co-author DOI 10.1186/s12943-017-0701-0↗
  16. Lipoxin A4 reverses mesenchymal phenotypes to attenuate invasion and metastasis via the inhibition of autocrine TGF-β1 signaling in pancreatic cancer. Co-author DOI 10.1186/s13046-017-0655-5↗
  17. Reactive Oxygen Species and Targeted Therapy for Pancreatic Cancer. Co-author DOI 10.1155/2016/1616781↗
  18. The Relevance of Nrf2 Pathway and Autophagy in Pancreatic Cancer Cells upon Stimulation of Reactive Oxygen Species. Co-author DOI 10.1155/2016/3897250↗
  19. Hyperglycemia Promotes the Epithelial-Mesenchymal Transition of Pancreatic Cancer via Hydrogen Peroxide. Co-author DOI 10.1155/2016/5190314↗
  20. β2-adrenogenic signaling regulates NNK-induced pancreatic cancer progression via upregulation of HIF-1α. Co-author DOI 10.18632/oncotarget.5677↗
  21. YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine. Co-author DOI 10.3390/nu8100546↗
  22. Resveratrol in the treatment of pancreatic cancer. Co-author DOI 10.1111/nyas.12837↗
  23. Overexpression of Nodal induces a metastatic phenotype in pancreatic cancer cells via the Smad2/3 pathway. Co-author DOI 10.18632/oncotarget.2686↗
  24. Ginkgolic acid suppresses the development of pancreatic cancer by inhibiting pathways driving lipogenesis. Co-author DOI 10.18632/oncotarget.3663↗
  25. miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. Co-author DOI 10.18632/oncotarget.3686↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 23 shared papers, 2015–2023 · strength 1.58
  2. Wanxing Duan · 18 shared papers, 2015–2019 · strength 1.10
  3. Cancan Zhou · 13 shared papers, 2016–2023 · strength 1.01
  4. Weikun Qian · 10 shared papers, 2017–2023 · strength 0.82
  5. Jiguang Ma · 13 shared papers, 2015–2019 · strength 0.79
  6. Xuqi Li · 13 shared papers, 2015–2019 · strength 0.75
  7. Zheng Wang · 11 shared papers, 2015–2023 · strength 0.74
  8. Liang Cheng · 10 shared papers, 2017–2019 · strength 0.73
  9. Zheng Wu · 8 shared papers, 2015–2023 · strength 0.61
  10. Liankang Sun · 9 shared papers, 2016–2019 · strength 0.59
  11. Bin Yan · 8 shared papers, 2017–2019 · strength 0.57
  12. Ke Chen · 8 shared papers, 2016–2018 · strength 0.54
  13. Jianjun Lei · 10 shared papers, 2015–2018 · strength 0.52
  14. Qinhong Xu · 10 shared papers, 2015–2018 · strength 0.52
  15. Junyu Cao · 7 shared papers, 2017–2019 · strength 0.50
  16. Liang Zong · 7 shared papers, 2015–2018 · strength 0.39
  17. Xin Chen · 5 shared papers, 2015–2018 · strength 0.30
  18. Ligang Nan · 6 shared papers, 2015–2016 · strength 0.27
  19. Erxi Wu · 5 shared papers, 2015–2019 · strength 0.27
  20. Jie Li · 4 shared papers, 2017–2018 · strength 0.27
  21. Wei Li · 4 shared papers, 2016–2018 · strength 0.26
  22. Lun Zhang · 4 shared papers, 2015–2016 · strength 0.21
  23. Zhenhua Ma · 4 shared papers, 2015–2017 · strength 0.21
  24. Simei Zhang · 1 shared paper, 2023 · strength 0.16
  25. Wunai Zhang · 1 shared paper, 2023 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.